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Abstract
Background: Nosocomial infections remain an important source of morbidity, mortality, and increased health care
costs in hospitalized patients. This is particularly problematic in intensive care units (ICUs) because of increased patient
vulnerability due to the underlying severity of illness and increased susceptibility from utilization of invasive therapeutic
and monitoring devices. Lactoferrin (LF) and the products of its breakdown have multiple biological effects, which
make its utilization of interest for the prevention of nosocomial infections in the critically ill.
Methods/design: This is a phase II randomized, multicenter, double-blinded trial to determine the effect of LF on
antibiotic-free days in mechanically ventilated, critically ill, adult patients in the ICU. Eligible, consenting patients will be
randomized to receive either LF or placebo. The treating clinician will remain blinded to allocation during the study;
blinding will be maintained by using opaque syringes and containers. The primary outcome will be antibiotic-free days,
defined as the number of days alive and free of antibiotics 28 days after randomization. Secondary outcomes will include:
antibiotic utilization, adjudicated diagnosis of nosocomial infection (longer than 72 h of admission to ICU), hospital and
ICU length of stay, change in organ function after randomization, hospital and 90-day mortality, incidence of tracheal
colonization, changes in gastrointestinal permeability, and immune function. Outcomes to inform the conduct of a larger
definitive trial will also be evaluated, including feasibility as determined by recruitment rates and protocol adherence.
Discussion: The results from this study are expected to provide insight into a potential novel therapeutic use for LF
in critically ill adult patients. Further, analysis of study outcomes will inform a future, large-scale phase III randomized
controlled trial powered on clinically important outcomes related to the use of LF.
Trial registration: The trial was registered at www.ClinicalTrials.gov on 18 November 2013. Trial registration number:
NCT01996579.
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Background
Nosocomial infections (NIs) remain an important cause
of morbidity, mortality, and increased health care costs
in hospitalized patients [1–3]. This is particularly prob-
lematic in intensive care units (ICUs) where NIs occur
in 25 to 35 % of ICU patients and account for approxi-
mately 25 % of all nosocomial infections in the hospital
[4, 5]. In ICU patients, mechanical ventilation is an
important risk factor for NIs as more than two thirds of
infections originate at three major sites: the respiratory
tract, the blood stream, and the urinary tract [6].
Further, since NIs are increasingly caused by multidrug-
resistant bacteria, clinicians frequently prescribe broad
spectrum antibiotic regimens. In turn, this sets the stage
for pseudomembranous colitis (PMC), another poten-
tially lethal NI [7]. The prevention of NIs has the poten-
tial to improve patient outcomes and reduce the cost
burden of increasingly broad spectrum, prolonged
courses of antibiotics administered for suspected or
confirmed infections.
Lactoferrin (LF), an 80-kDa, multifunctional glycoprotein
of the transferrin family, is distributed widely in humans
particularly in secretions of exocrine glands and specific
neutrophil granules. The highest concentrations of LF are
found in breast milk and colostrum. As an important
component of the human innate immune system, it has
many appealing properties that may prove effective for the
prevention of NIs [8]. LF has the ability to bind iron, an
important element for microbial growth, thereby reducing
its availability to microorganisms and making it bacterio-
static [9–11]. In addition, LF has bactericidal effects on
microorganisms attributable to its highly cationic charged
terminus, which binds to bacterial surfaces [12]. The bind-
ing of LF to the bacterial surface destabilizes the bacterial
outer membrane, thus enhancing bacterial susceptibility to
osmotic shock, lysozyme, or other antimicrobial molecules
[13–15]. This antibacterial activity has been documented
against many important human pathogens, including:
Escherichia coli, Staphylococcus aureus, Klebsiella sp.,
Acinetobacter sp., Pseudomonas sp., Salmonella sp., and
Proteus sp. [16–18]. Additionally, LF has been shown to
exhibit activity against Candida albicans and Candida
krusei and to inhibit the formation of biofilms by
Pseudomonas aeruginosa and oral bacteria [19–21]. This
may be an important attribute of LF as biofilm formation is
a large contributor to device-related infections [22].
Other reported effects of LF include its ability to
neutralize lipopolysaccharide (LPS) and promote the
growth of beneficial bacteria in the GI tract including
Bifidobacteria [23, 24]. Lastly, LF has the ability to
modulate the immune system including increasing the
size of Peyer’s patches, increasing serum immunoglobulin
levels, decreasing inflammatory cytokines and increasing
anti-inflammatory cytokines such as interleukin-10 (IL-10)
[25]. In healthy human volunteers, the administration of
bovine lactoferrin (bLF) was associated with increased
T-cell activation (total, helper, and cytotoxic) and increased
antioxidant status [26]. Although LF is a polypeptide, it is
resistant to digestion in the digestive tract with 60 to 80 %
of bovine LF exiting the stomach intact [27]. Biologically
active peptides survive after transit through the small
intestine with antibacterial activity remaining similar or
increased compared to intact LF [28–30].
The properties of LF make it a potential tool for the
prevention of NIs in critically ill patients since its enteral
administration may reduce the overgrowth of pathogens,
which is an important cause of NIs in the critically ill
[31]. We hypothesize that the administration of LF per
os and via the nasogastric route to critically ill mechan-
ically ventilated patients will reduce NIs, reduce anti-
biotic usage, and result in improved patient outcomes
and survival. To test our hypothesis, we will first
conduct a phase II randomized control trial (RCT) of LF
for prevention of NIs with antibiotic-free days as the
primary outcome supported by biomarker and mechan-
istic data. The data from this study will inform whether
to proceed to a larger definitive study. Herein we report
the protocol for the phase II study which is written in
accordance with standardized reporting guidance from
SPIRIT (see Additional file 1).
Methods/design
A phase II randomized, multicenter, double-blinded trial
in five Canadian tertiary ICUs. Study sites include:
Kingston General Hospital (Kingston, ON), Hôpital du
Sacré-Coeur de Montréal (Montreal, QC), Sherbrooke
(Sherbrooke, QC), Royal Columbian Hospital (New
Westminster, BC), and Ottawa Hospital (Ottawa, ON).
An overview of the study process is provided in Fig. 1.
Study population
Adult mechanically ventilated patients in the ICU
meeting all of the inclusion criteria and none of the
exclusion criteria.
Inclusion criteria
1. Adult patients (aged 18 years or older)
2. Invasive mechanical ventilation for 48 h or less
3. Patient is expected to be mechanically ventilated
for longer than 72 h
Exclusion criteria
1. Patient is expected to be in ICU for less than 72 h
from the time of randomization (due to imminent
death, withdrawal of life sustaining therapies, or
discharge)
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2. Presence of a contraindication to enteral feeding
3. Lack of access to the oral cavity
4. An allergy or sensitivity to LF or bovine-derived
proteins or milk
5. Patient is immunocompromised (post organ
transplantation, acquired immunodeficiency
syndrome (AIDS), neutropenia (fewer than 1000/cc
absolute neutrophils), corticosteroids (more than 20
mgs/day of prednisone or equivalent for more than
6 months))
6. Fulminant liver failure or end stage liver disease
(Child’s class C)
7. Life expectancy less than 6 months due to
preexisting conditions
8. Patient is pregnant or lactating
9. Enrollment in an industry-sponsored interventional
trial (coenrollment in other interventional studies
allowed if there is no interaction between the
interventions)
10.Patient has undergone prior randomization in this
study
Study intervention
Patients will be randomized to receive LF or placebo.
Patients randomized to the LF arm will receive LF
solutions delivered to the oral cavity as a mouth swab
and LF down a nasogastric tube. The LF used for the
study will be bLF, supplied by Advanced Orthomolecular
Research [32]. The dosage of bLF will be a total of 2 g
administered in four divided doses per day which is
similar to that used in other human studies. Following
enrollment, the study intervention will start within 6 h
of randomization. Study treatment will be discontinued
after 28 days from the time of randomization, permanent
removal of the feeding tube, or death, whichever occurs
first. All patients will receive standard ICU care for
critically ill mechanically ventilated patients. The prescrip-
tion of antibiotics will be left to the treating team.
Random allocation
A password-protected web-based central randomization
system is used to allocate patients to study treatments
such that investigators, research staff and patients are
blinded to the next allocation and an audit trial is
maintained. Clinicians will remain blinded during the
study, which will be maintained by administering LF or
placebo in opaque syringes such that the placebo and
active solutions are indistinguishable from each other.
Randomization will be stratified by site using permuted
blocks of variable size. The randomization list will be
computer-generated by the trial biostatistician using
SAS (SAS Inc., Cary, NC, USA) and securely stored by
the study biostatistician and the IT manager of the
central randomization system.
Follow-up
Patients will be followed daily until day 28. Mortality will
be determined for the ICU stay, hospital stay, and at
90 days. All patients will have blood samples drawn for
biomarkers (C-reactive protein (CRP), procalcitonin
(PCT), and IL-6), as well as for genome-wide expression
profiling, at baseline and on days 3, 7, 14, 21, and 28.
Cytokines will be measured using multiplex enzyme-
linked immunosorbent assays (ELISAs), with samples
Fig. 1 An overview of the study process
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prepared on site and shipped to a central laboratory for
processing. Blood for gene expression analysis will be
collected in PAXgene tubes, frozen according to the
manufacturer’s protocol, and shipped to a central
genomics facility for ribonucleic acid (RNA) extraction
and expression profiling using the Affymetrix PrimeView
microarray [33, 34]. Tracheal samples for bacterial
cultures will be obtained at baseline and on days 3, 7,
14, 21, and 28. In addition, given the nature of the inter-
vention, no specific provisions have been made for
ancillary or post-trial care of participants.
Adverse events
All patients will be monitored closely for the develop-
ment of serious adverse events, and reported as per
Good Clinical Practice [35], Health Canada [36] and
local ethics’ requirements. For serious adverse events, a
form on the electronic Case Report Form (eCRF) is
completed by local research personnel to capture the
pertinent data.
Protocol violations
A protocol violation is defined as noncompliance with
the study protocol and/or procedures. For protocol
violations, local research personnel are required to
complete a protocol violation report that is reported to
the study leader.
Data management
Enrolled patients are assigned a numeric identifier to main-
tain confidentiality and no personal identifiers are collected.
All study data is entered into an eCRF (REDCap) [37],
which is housed on a secure server at Queen’s University,
Kingston, ON. Paper-based study material is stored in a
secure location, with access limited to study personnel.
Primary outcomes
The primary outcome for this phase II study will be
antibiotic-free days, defined as being alive and free of
antibiotics 28 days after randomization. This measure is
similar to ventilator-free days, which is widely used in
the critical care literature and incorporates antibiotic
status, ICU status, and mortality in the 28 days from
study enrollment [38].
Secondary outcomes
1. Feasibility (recruitment rates, protocol adherence,
data completeness, and time required to capture
data): the goal for the recruitment rate will be an
average of 0.75 patients per week/per site. Protocol
adherence will be considered successful if more than
80 % protocol adherence is achieved. Evaluation of
protocol adherence will include administration of
study medications, obtaining biological samples and
carrying out laboratory testing protocols. The goal
for data completeness is 100 %, but success will be
defined at knowing the status of more than 95 % of
the 28-day outcomes. Lastly, the time needed to
capture required data will be used to determine the
budget and feasibility of a future definitive RCT
2. Clinical outcomes: antibiotic utilization will be
measured by the prescription of new antibiotics after
72 h of admission to ICU, and number of defined
daily doses (DDD) of antibiotics. Blinded central
adjudication of nosocomial infection (longer than
72 h from admission to ICU) will be determined
using standardized definitions and procedures.
Change in organ function post randomization will
be measured using the Sequential Organ Failure
Assessment (SOFA) score [39]. We will also record
hospital and ICU length of stay, and hospital
survival and 90-day mortality
3. Laboratory and biochemical outcomes: the effects of
LF will be evaluated using biomarker analysis,
i.e., measurement of levels of sequential PCT,
CRP, and IL-6 at baseline, day 3, day 7 and
then weekly until 28 days post randomization.
Gastrointestinal permeability will be measured
using the Lactulose/Mannitol Ratio at day 5 [40, 41].
Immune function will be evaluated based on the
production of tumor necrosis factor alpha (TNF-α)
in response to an LPS stimulation assay [42]. Rates of
tracheal colonization will be determined by the number
of tracheal samples positive for potential pathogens
4. Genomics substudy: the biological mechanisms of
LF action will be explored using gene expression
profiling. In a subset of patients (continuously
recruited from one study site), an additional tube
of blood will be collected at the abovementioned
time points for RNA extraction and gene expression
profiling. Bioinformatic analyses will examine
differences in gene expression at baseline between
control and treatment groups, changes in the
treatment group in response to therapy, and




From a study that enrolled a similar population, the
mean and standard deviation of antibiotic-free days was:
mean (SD), 14 (9) [43]. A 25 % increase in antibiotic-free
days would be clinically significant and feasible if LF has
the expected biological activity. To detect a 25 %
increase in antibiotic-free days to 17.5 days in the inter-
vention arm with 80 % power at a two-sided alpha of
0.05, a sample size of 210 (105 subjects per arm) is
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required. We believe that this sample size will be
adequate to reliably assess all feasibility and laboratory out-
comes but may not be powered for all clinical outcomes.
Analysis of primary and secondary outcomes
The main analysis will provide a histogram showing the
distribution of the antibiotic-free days per arm. Although
the antibiotic-free days will not be normally distributed,
the sample is large enough that the mean will be
approximately normally distributed, so the mean differ-
ence with corresponding 95 % confidence intervals and
p values will be estimated by an analysis of variance
blocking by site. A sensitivity analysis will use an exact
permutation test stratified by site to confirm the main
conclusion. For transparency we will report both the
primary and sensitivity analysis.
Feasibility outcomes will not be compared by arm but
will be provided overall using descriptive statistics (re-
cruitment rates, adherence and completeness propor-
tions and mean time needed to capture required data).
Since there are multiple clinical outcomes that may have
low power, we will avoid formal hypothesis testing and
focus on presenting the between-arm difference in
means or proportions with 95 % confidence intervals.
All clinical analyses will control for site.
The distribution of the laboratory and biochemical
outcomes will be depicted by arm over time using
clustered boxplots. Statistical significance between arms
at each time point will be tested by the Wilcoxon-rank
sum test, but the multiplicity of tests and clinical
important of differences will be considered when
interpreting statistical significance. All analysis will
adhere to the intent-to-treat principle. We expect the
amount of missing data to be trivial (less than 5 %), but
details of any missing data will be reported.
Subgroup and interim analysis
Due to conflicting results on the effects of LF when used
as a treatment for sepsis [44, 45] a priori, we will
conduct a subgroup analysis of patients presenting with
sepsis [46]. No formal interim analyses are planned.
Dissemination
Protocol amendments
Protocol amendments are communicated to the Research
Ethics Boards (REBs)/Institutional Review Boards, project
sites, and regulatory agencies. The primary means of
communication is via email for study management. Any
issues requiring acute attention, or of great significance
would be managed via teleconference.
Dissemination policy
The authors intend to communicate the trial results via
a published manuscript and abstract; however, public
access to the participant-level dataset and statistical code
will not be granted.
Discussion
There is extensive medical literature on the prevention of
nosocomial infections and multiple clinical practice guide-
lines for their prevention have been published [47–49].
Although rates of nosocomial infections have decreased in
recent years, they continue to occur since present prevent-
ive measures are only partially effective [50]. New
techniques to reduce the occurrence of nosocomial infec-
tions continue to be required and LF has many properties
that may make it an ideal agent for this. If the results of
this phase II study suggest potential efficacy of LF for the
prevention of NIs in mechanically ventilated patients, it
will inform the conduct of a larger definitive study. This
program of research has the potential to change practice
and may improve the morbidity and mortality of critically
ill patients.
The human clinical studies of LF that have been
reported are mainly observational, although randomized
trials have been reported. The majority of RCTs with LF
have been on the treatment of Helicobacter pylori, these
reporting on LF in neonates to either prevent sepsis or
nosocomial infections and as treatment for sepsis in
adults. A meta-analysis reporting on nine RCTs enrolling
1343 patients on the effect of adding LF to standard
therapy found that LF increased the rate of Helicobacter
pylori eradication (odds ratio (OR) = 2.26, 95 % CI 1.70
to 3.00) and reduced the rate of adverse effects (OR =
0.15, 95 % CI 0.04 to 0.54) [51]. One RCT reported on
the effect of bLF administered to very-low-birth-weight
neonates; the administration of bLF was associated with
a reduced risk of sepsis (risk ratio 0.34, 95 % CI 0.17 to
0.70, p = 0.002) [52]. A trial for the prevention of
ventilator-associated pneumonia (VAP) in critically ill
neonates recently reported that there were no local side
effects of the orally administered treatment containing
LF, and a lower, but not statistically significant rate of
VAP was found in the treatment group (9/1000
ventilator-days versus 17/1000 ventilator-days in placebo
group, respectively; p = 0.16) [53].
There have been two completed trials of human
recombinant lactoferrin (hLF) for the treatment of
sepsis. In the first trial of hLF for the treatment of severe
sepsis in190 patients, the administration of hLF was
associated with a 12.5 % reduction in 28-day all-cause
mortality (26.9 % versus 14.4 %, p = 0.05) [44, 54]. The
reduction in mortality was maintained at 3 and 6 months
[55]. A second trial utilized similar enrollment criteria
and treatment in randomizing 205 patients. The 28-day
all-cause mortality in the hLF arm was 25 % compared
to 18 % in the placebo group (p = 0.11), although ICU
and long-term mortality were increased in the hLF
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group [45]. However, on combining the results of the
two trials in a meta-analysis, the relative risk of hospital
mortality was 0.88 (95 % CI 0.35 to 2.26) (unpublished
data).The cause for the discrepant results between these
studies is unknown.
In summary, although LF has many biological properties
which may be beneficial in critically ill patients, investiga-
tions thus far have yielded conflicting results. A potential
use of LF is for the prevention of NIs and this trial is
designed to yield preliminary results in this regard to guide
future investigations.
Trial status
The study began recruiting patients in Kingston, ON in
November 2013, and expanded to the additional tertiary
sites in September 2014. Recruitment is estimated to
continue until July 2016. The final report will be pre-
pared for 2016.
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